GD2-targeting immune cells for solid tumors
Part of Cancer clinical trials.
This study tests a special immune cell treatment (CAR T cells) that targets a marker called GD2 on solid tumor cells. It is for people whose cancer has not responded to standard treatments or has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 65 years old and weigh at least 22 pounds (10 kg).
- Your tumor must have a marker called GD2, which the study will test for.
- You have already tried standard treatment, but your cancer either did not go away, came back, or spread.
- You need to be reasonably healthy, with your heart, lungs, liver, and kidneys working well enough.
- Your blood counts must be above certain minimum levels.
- You cannot have untreated cancer that has spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR-T cells that are designed to find and attack cancer cells that have a specific marker (GD2 or PSMA). It is for people whose cancer has not been controlled by standard treatment, and it aims to see if this therapy is safe and effective.
This trial tests a special type of cell therapy called CAR T cells. The cells are changed in the lab to find and attack a protein called CD276 on the surface of solid tumors. If the treatment works, your own immune cells could shrink the tumor or slow its growth.
This trial tests a new type of immune cell therapy (CAR gamma-delta T cells) for advanced solid tumors that have not responded to standard treatments. The therapy uses donor cells that are specially trained to find and attack cancer cells.
This trial tests a new type of immune cell therapy called KD-496, which is a CAR T-cell designed to attack tumors that have NKG2DL or CLDN18.2 markers. It may be an option for people with advanced solid tumors (commonly stomach or pancreatic cancer) who have tried at least two prior treatments.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack tumors with specific markers (GD2 or CD70). It may be an option for patients whose cancer has not responded to standard treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.